Amersen

Amersen Biotech is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of next-generation gene therapies. The company leverages its proprietary AAV-X platform for high-throughput capsid engineering and vector optimization to create highly efficient and tissue-specific delivery vehicles. Amersen's pipeline focuses on addressing unmet medical needs in ophthalmology, neurology, and rare genetic disorders, with its lead program targeting Leber congenital amaurosis. By optimizing vector design and manufacturing processes, the company aims to improve the safety, efficacy, and accessibility of gene-based treatments. Amersen is supported by leading venture capital investors and maintains a strong focus on translational research and clinical development.